Key references: Adjunctive antihyperglycaemics for adults with type 1 diabetes

  • Chen J, Fan F, Wang JY, Long Y, Gao CL, Stanton RC, et al. The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis. Sci Rep 2017;7:44128. https://www.ncbi.nlm.nih.gov/pubmed/28276512
  • Dandona P, Mathieu C, Phillip M, Hansen L, Griffen SC, Tschope D, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2017;5(11):864–76. https://www.ncbi.nlm.nih.gov/pubmed/28919061
  • Dejgaard TF, Frandsen CS, Hansen TS, Almdal T, Urhammer S, Pedersen-Bjergaard U, et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2016;4(3):221–32. https://www.ncbi.nlm.nih.gov/pubmed/26656289
  • Garg SK, Peters AL, Buse JB, Danne T. Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol. Diabetes Technol Ther 2018;20(9):571-5. https://www.ncbi.nlm.nih.gov/pubmed/30129772
  • Libman IM, Miller KM, DiMeglio LA, Bethin KE, Katz ML, Shah A, et al. Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: A randomized clinical trial. JAMA 2015;314(21):2241–50. https://www.ncbi.nlm.nih.gov/pubmed/26624824
  • Mathieu C, Rudofsky G, Phillip M, Araki E, Lind M, Arya N, et al. Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial. Diabetes Obes Metab 2020;22(9):1516-26. https://www.ncbi.nlm.nih.gov/pubmed/32311204
  • Petrie JR, Chaturvedi N, Ford I, Brouwers M, Greenlaw N, Tillin T, et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2017;5(8):597–609. https://www.ncbi.nlm.nih.gov/pubmed/28615149
  • Rao L, Ren C, Luo S, Huang C, Li X. Sodium-glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials. Acta Diabetol 2021;58(7):869-80. https://www.ncbi.nlm.nih.gov/pubmed/33651228
  • Wang W, Liu H, Xiao S, Liu S, Li X, Yu P. Effects of insulin plus glucagon-like peptide-1 receptor agonists (GLP-1RAs) in treating type 1 diabetes mellitus: a systematic review and meta-analysis. Diabetes Ther 2017;8(4):727–38. https://www.ncbi.nlm.nih.gov/pubmed/28616805